Cell Therapy for Cardiovascular Disorders - Applications of Biotechnology in Cardiovascular Therapeutics - page 207

Chronic myocardial
ischemia/reduced
pumping function

Direct intramyocardial injection of autologous CD133+
bone marrow stem cells in addition to in patients who also
had CABG

Phase I/II
randomized

Miltenyi Biotec/Heart Centers in
Rostock, Berlin, and Hannover

Congestive heart failure
needing ventricular
assist device

Injection of 25-45 million autologous bone marrow-derived
stem cells into the diseased myocardium during VAD
implant procedure

Open trial on
5-10 patients

University of Pittsburgh Medical
Center (Pittsburgh, PA)

Coronary artery
disease, myocardial
infarction,
congestive heart
failure

MYOHEART (Myogenesis heart efficiency and regeneration trial) Phase I Bioheart Inc

Drug: MyoCell ™
Device: MyoCath ™

Coronary artery
disease, myocardial
infarction,
congestive heart
failure

Intracoronary infusion of stem cells for safety and efficacy studies Phase I Amorcyte Inc/Emory University

School of Medicine
(Atlanta, GA)

Coronary artery disease,
candidates for
bypass surgery

Autologous bone marrow stem cells to be injected directly into
open hearts during surgery

Phase I University of Utah, Salt Lake City

Coronary artery disease,
unsuitable for
treatments such as
coronary stenting
or bypass surgery

Targeted intracoronary and intramyocardial injection of bone
marrow-derived adult HSCs using MYOSTAR ™ injection
catheter and NOGA ® cardiac navigation system
(cordis corporation). The results were satisfactory

Pilot trial University of Vienna Medical Center

(Vienna, Austria)

Coronary artery
disease, severe with
myocardial damage

Autologous cultured stem cells delivered by cardiac catheter
improved heart failure/cardiac function within 3 months
and met safety endpoint of 6 months

Pilot trial on
six patients

Mesoblast Ltd/angioblast systems

Dilated
cardiomyopathy,
with heart failure

Autologous stem cell therapy: Cardiac Repair Cells (CRCs),
generated from the patient's bone marrow, injected directly
into the heart muscle

Open study
on patients
completed

Aastrom Biosciences/University
Hospital (Dusseldorf, Germany)

(continued)